DrugPatentWatch Database Preview
Details for Biologics License Application: 103948
Email this page to a colleague
» See Plans and PricingSummary for BLA: 103948
| Tradename: | LEMTRADA |
| Applicant: | Genzyme |
| Ingredient: | alemtuzumab |
| Patents: | 362 |
| Approval Date: | May 07, 2001 |
Pharmacology for BLA: 103948
| Drug Class | CD52-directed Cytolytic Antibody |
| Mechanism of Action | CD52-directed Antibody Interactions |
US Patents for BLA: 103948
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) | 2028-04-10 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | University of Georgia Research Foundation, Inc. (Athens, GA) | 2039-02-26 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | AbbVie Stemcentrx LLC (North Chicago, IL) | 2033-02-08 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
